.png)
.png)
Latest news from BIA
The BioIndustry Association announces 2020 charity partnership with Versus Arthritis
The BioIndustry Association (BIA) is proud to be working with Versus Arthritis as its charity partner for 2020.
Sharon Grimster (ReNeuron) and Sarah Goulding (Knowledge Transfer Network) to be recognised at bioProcessUK conference
Sharon Grimster of ReNeuron and Dr Sarah Goulding of the Knowledge Transfer Network (KTN) will be awarded the prestigious Peter Dunnill award and Richard Wilson impact award respectively, at the UK BioIndustry Association’s (BIA) 16th bioProcessUK conference in Liverpool later this month.
BIA launches biotech manifesto
The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has today launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.
BIA responds to the Smith - Reid Review on international research partnerships
Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) said: “Thanks to new advances in science and innovation, we are at the cusp of a new industrial revolution, however Brexit is causing much uncertainty for UK SMEs. I welcome the publication of this important review and it is good to see the Science Minister recognising the valuable contribution the life sciences sector makes in discovering new cures for life-threatening diseases.
Green light for planning permission at Plot 16 as The Oxford Science Park continues ambitious expansion plans
Oxford, UK, December 5 2019 - Oxford City Council’s East Area Planning Committee has approved the detailed plans for two office / laboratory buildings on The Oxford Science Park’s Plot 16 comprising 168,000 sq ft (15,600 sq m). The plans feature a central raised plaza and wider landscaping and accessibility enhancements.
Mogrify wins Innovation Award and Dr. Jane Osbourn, OBE receives Lifetime Achievement Award at Scrip Awards 2019
• Mogrify platform recognized as having potential to transform future development of new medicines at prestigious awards ceremony • Mogrify Chair receives Lifetime Achievement Award for contributions to biologics discovery and development
Arecor announces positive headline results for the first Phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin
Favourable pharmacokinetic/pharmacodynamic profile compared to current best in class insulin treatment Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247. In the study, AT247 provided a favourable pharmacokinetic/pharmacodynamic profile compared with NovoRapid® and Fiasp®.
Horizon Discovery partners with the Human Protein Atlas
• Horizon’s HAP1 cell line to be integrated in the HPA Cell Atlas program • Knockout cell models from Horizon chosen based on consistency and reproducibility demonstrated in validation studies • Agreement will expand open access resource, supporting genetic research globally
BPE joined line up for 16th annual bioProcessUK conference
As one of the few specialists in the UK for chemical and biochemical engineering design, the BioIndustry Association’s bioProcessUK conference is an extremely important annual meeting for us to meet our customers and share the latest industry trends in biologics manufacturing.
CEO Update|Monday 02 December 2019
It was a real pleasure to see so many of you up in Liverpool last week for our bioProcessUK conference.
Guest Blog|Bringing medical innovation into the market in the UK and internationally
Insights from the IQVIA Biotech UK conference, 2019 What’s the state of Biotech in the UK and beyond – in terms of funding, innovation, policy and commercialisation? European Thought Leadership’s Sarah Rickwood chaired a panel at IQVIA Biotech conference on November 7th, in a conference attended by financiers, policy makers, biotech entrepreneurs and scientists.
BIA analysis of party manifestos
In this blog, the BIA’s policy and public affairs team helps you cut through the election noise by summarising what the parties’ manifesto policies mean for biotech.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
